Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies

AIDS Research and Therapy

Mario Stevenson²  Nicolas Chomont³  Alain Lafeuillade¹ 

[1] Department of Infectious Diseases, General Hospital, 1208 avenue Colonel Picot, 83056, Toulon, France

[2] Division of Infectious Diseases, University of Miami Leonard M. Miller School of Medicine, Two Story Lab (TSL), 1420 NW 9th Avenue (T-190), Room 109, Miami, Fl 33136, USA

[3] Vaccine and Gene Therapy Institute, 11350 SW Village Parkway, Port St Lucie, Fl 34987, USA

关键词: HIV reservoir group;    HIV eradication;    HIV cure;    HIV latency;    HIV reservoirs;    HIV persistence;   

Others  :  789675
DOI  :  10.1186/1742-6405-9-7

 received in 2012-02-02, accepted in 2012-03-12,  发布年份 2012

【 摘 要 】

The December 2011 5^th International Workshop on HIV Persistence during Therapy addressed the issue of HIV persistence among 210 scientists from 10 countries involved in the study of HIV reservoirs and the search of an HIV cure. High quality abstracts were selected and discussed as oral or poster presentations. The aim of this review is to distribute the scientific highlights of this workshop outside the group as analyzed and represented by experts in retrovirology, immunology and clinical research.

【 授权许可】

   
2012 Stevenson et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Lewin SR, Evans VA, Elliott JH, Spire B, Chomont N: Finding a cure for HIV: will it ever be achievable? J Int AIDS Soc 2011, 14:4. BioMed Central Full Text
• [2]Tyagi M, Romerio F: Models of HIV-1 Persistence in the CD4+ T Cell Compartment: Past, Present and Future. Curr HIV Res 2011, in press.
• [3]Bosque A, Novis C, Martins L, Ramirez P, Famiglietti M, Planelles V: HIV-1 Latency in in vitro Differentiated Central Memory Cells. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 03. [http://www.ihlpress.com/pdffiles/AbstractBook_PW2011_online.pdf] webciteGlobal Antiviral J 2011, 7(suppl 2):4-5.
• [4]Garcia JV: Generation of HIV Latency in BLT Humanized Mice. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 04. Global Antiviral J 2011, 7(suppl 2):5-6.
• [5]Clements JE, Russell JN, Gama L, Engle EL, Mankowski JL, Zink MC: The Brain and Spleen are Reservoirs of SIV Infection in Macrophages. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 36. Global Antiviral J 2011, 7(suppl 2):29-30.
• [6]Russell JN, Engle EL, Zink MC, Gama L, Clements JE: The Contribution of Splenic Macrophages to SIV Infection and Changes in this Population Following Antiretroviral Treatment. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 05. Global Antiviral J 2011, 7(suppl 2):6.
• [7]Trono D, Van Lint C, Rouzioux C, et al.: HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010, 329(5988):174-180.
• [8]Lewin S: The Role of Chemokines in the Establishment of HIV Latency. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 38. Global Antiviral J 2011, 7(suppl 2):30-31.
• [9]Yan N, Wheeler LA, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J: The Cytosolic Exonuclease TREX1 Digests HIV Reverse Transcripts to Avoid Triggering an Antiviral Interferon Response in T-cells and Macrophages. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 21. Global Antiviral J 2011, 7(suppl 2):19.
• [10]Laguette N, Benkirane M: How Samhd1 May Change our View of Viral Restriction. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 23. Global Antiviral J 2011, 7(suppl 2):20.
• [11]Laguette N, Sobhian B, Casartelli N, et al.: SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011, 474(7353):654-657.
• [12]Hrecka K, Hao C, Gierszewska M, et al.: Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011, 474(7353):658-661.
• [13]Lahaye X, Silvin A, Satoh T, Conrad C, Littman DR, Manel N: Innate Immunity & Establishment of HIV Reservoirs. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 22. Global Antiviral J 2011, 7(suppl 2):19-20.
• [14]O'Doherty U: Relevance of Monitoring HIV viral DNA intermediates in vivo. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 25. Global Antiviral J 2011, 7(suppl 2):21.
• [15]Graf EH, Mexas AM, Yu JJ, et al.: Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV + patients on and off HAART. PLoS Pathog 2011, 7:e1001300.
• [16]Buzon MJ, Seiss K, Weiss R, et al.: Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers. J Virol 2011, 85:9646-9650.
• [17]Buzon MJ, Yang Y, Seiss K, Pereyra F, Yu XG, Lichterfeld M: Increased Susceptibility to CD8 T Cell Mediated Killing Limits the HIV-1 Reservoir in Naïve CD4 T Cells from Elite Controllers. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 28. Global Antiviral J 2011, 7(suppl 2):22-23.
• [18]Deeks SG: The Impact of HIV-associated Inflammation on HIV Persistence. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 26. Global Antiviral J 2011, 7(suppl 2):21.
• [19]Plaeger SF, Collins BS, Musib R, Deeks SG, Read S, Embry A: Immune Activation in the Pathogenesis of Treated Chronic HIV Disease: A Workshop Summary. AIDS Res Hum Retroviruses 2011, in press.
• [20]Yukl S, Shergill AK, McQuaid K, et al.: Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010, 24:2451-2460.
• [21]Hatano H, Hayes TL, Dahl V, et al.: A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011, 203:960-968.
• [22]Chomont N: Immunological Mechanisms Involved in HIV Persistence: Keeping Memory, Keeping HIV. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 27. Global Antiviral J 2011, 7(suppl 2):22.
• [23]Vandergeeten C, DaFonseca S, Fromentin R, Sekaly RP, Chomont N: Differential Impact of IL-7 and IL-15 on HIV Reservoir Persistence. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 29. Global Antiviral J 2011, 7(suppl 2):23.
• [24]Chirullo B, Sgarbanti R, Lewis MG, et al.: Modulation of Oxidative Stress Induces Apoptosis in Long-Lived Phenotypes ex vivo. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 30. Global Antiviral J 2011, 7(suppl 2):23-24.
• [25]Lewis MG, Dafonseca S, Chomont N, et al.: Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS 2011, 25(11):1347-1356.
• [26]Savarino A, Mai A, Norelli S, et al.: "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 2009, 6:52. BioMed Central Full Text
• [27]Kuritzkes D: Designing Clinical Trials for HIV-1 Eradication. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 37. Global Antiviral J 2011, 7(suppl 2):30.
• [28]Lori F, Jessen H, Lieberman J, et al.: Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis 1999, 180:1827-1832.
• [29]Strain MC, Little SJ, Daar ES, et al.: Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005, 191:1410-1418.
• [30]Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al.: Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010, 24:1598-1601.
• [31]Markowitz M, Evering T, Garmon D, Caskey M, et al.: A Randomized, Open-Label Trial of 5-Drug versus Standard 3-Drug PI-based cART Initiated During Acute and Early Infection: 96-Week Results. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 31. Global Antiviral J 2011, 7(suppl 2):25-26.
• [32]Ananworanich J, Vandergeeten C, Schuetz A, Sereti I, et al.: The Effect of Mega-HAART and HAART Instituted During Fiebig I to IV Acute HIV Infection on HIV Reservoir Size and Gut T cells. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 32. Global Antiviral J 2011, 7(suppl 2):26-27.
• [33]Zack JA: Thoughts on Elimination of Latent HIV Reservoirs. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 11. Global Antiviral J 2011, 7(suppl 2):11.
• [34]Kovochich M, Marsden MD, Zack JA: Activation of latent HIV using drug-loaded nanoparticles. PLoS One 2011, 6(4):e18270.
• [35]Margolis D, Archin NM, Kuruc JD, et al.: The Effect of Vorinostat on Latent HIV-1 Expression in vivo: Preliminary Findings from a Clinical Study in ART-suppressed HIV-1-infected Patients. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 40. Global Antiviral J 2011, 7(suppl 2):31-32.
• [36]Hernandez B, Madrid N, Lamas M, Bermejo L, Moreno S: Maraviroc (MRV) can activate NFkB in patients infected with R5 or D/M HIV-1. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, abstract LB04. Global Antiviral J 2011., 7(suppl 2) Late breaker abstracts available at: http://www.hiv-reservoir.net/index.php/the-news/189-abstract-book-2011-hiv-persistence-workshop.html webcite
• [37]Huang L, Lee L, Chen CH: Picomolar Dichotomous Activity of Gnidimacrin against HIV-1 Latent Infection. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 43. Global Antiviral J 2011, 7(suppl 2):34-35.
• [38]Huang L, Ho P, Yu J, Zhu L, Lee KH, Chen CH: Picomolar dichotomous activity of gnidimacrin against HIV-1. PLoS One 2011, 6(10):e26677.
• [39]Sigal A, Kim JT, Balazs AB, et al.: Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011, 477(7362):95-98.
• [40]Schacker T, Stevenson M, Fletcher C: Anatomic HIV Reservoirs. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 35. Global Antiviral J 2011, 7(suppl 2):28-29.
• [41]Cohen J: Tissue Says Blood Is Misleading, Confusing HIV Cure Efforts. Science 2011, 334(6063):1614.
• [42]Tebas P, Stein D, Wang S, et al.: A Single Infusion of Zinc Finger Nuclease (ZFN) CCR5 Modified Autologous CD4 T-cells Correlates with Increases CD4 Counts and Effects on Viral Load in Aviremic HIV-infected Subjects. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 45. Global Antiviral J 2011, 7(suppl 2):36-37.
• [43]Jerome KR, Mintzer E, Baker D, Schiffer JT, Aubert M: Direct Targeting of Integrated HIV Sequences Using Engineered Homing Endonucleases. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 48. Global Antiviral J 2011, 7(suppl 2):37.